Athérome carotidien et prévention des AVCamcar.ma/ressources/att/journees/2015/KOWNATOR2.pdfA...
Transcript of Athérome carotidien et prévention des AVCamcar.ma/ressources/att/journees/2015/KOWNATOR2.pdfA...
Athérome carotidien
et
Prévention des AVC
AMCAR 2015
Serge Kownator
« Centre Cardiologique et Vasculaire »
Thionville
A propos d’AVC
• Environ 150 000 nouveaux cas/an en France
• Responsable de 60 000 décès
• Conséquences
– 1ère cause de handicap physique acquis
– 2ème cause de démence
– 3ème cause de mortalité
• 70 à 80% des survivants rentrent chez eux
– Mais handicap pour la moitié d’entre eux
• Coût majeur pour la société
3
Etiologie des AVC/ AIT
Athérosclérose
Plaque aortique
Cardiopathies
emboligènes
Plaque embolie
Sténose carotide
Fibrillation Atriale
Maladie Valvulaire
Thrombus du Ventricule gauche
Athérosclérose
Intracrânienne
25%
30% : Cause rare ou cause non identifiée German Stroke Data Bank, Stroke 2001, 32 : 2559-66
Maladie des petites
artères
20%
25%
25%
Risk factors for stroke
Interstroke
O’Donnell MJ et al. the INTERSTROKE study. Lancet 2010; 376: 112–23
Carotid atherosclerosis
Definitions – Intima media thickness
• “Double line” pattern between the luminal edge of the artery and the
boundary between media and adventitia
– Plaque
• Focal structure encroaching in the lumen
• > 0.5mm or > 50 % of the surrounding IMT
• Or > 1.5 mm wall thickness
– Stenosis
• Plaque leading to an obstruction ≥ 50 %
Touboul PJ et al. Cerebrovasc Dis. 2012;34(4):290-6.
Hypertension increases atherogenic
lipoprotein content of arterial vessel walls
Sposito AC. Eur Heart J Suppl. 2004;6(suppl G):G8-G12.
BP
Atherogenic
VLDL, VLDL-R,
IDL, LDL
Intima- Enhanced – LP penetration
media – LP retention
– Pressure-induced distension
– Stretching
Intima-
media
Pressure-driven
convection
Relation of Common Carotid Intima-Media
Thickness With First-Time Myocardial
Infarction or Stroke Across Studies
• Hazard ratios are per 0.1 mm increase in CCA-IMT
Den Ruijter DM et al. JAMA. 2012;308(8):796-803
EIM et AVC
Bots et al Circulation 1997; 96: 1432–37.
<0.75 0.75 0.82
0.83 0.91
>= 0.92
Common CIMT (mm)
10
9
8
7
6
5
4
3
2
1
0
Rela
tive r
isk
(9
5%
CI)
Relationship between IMT & Plaque EVA study
• IMT value as a predictor
of 4 years atheromatous
plaque occurrence:
– OR = 2.6 for mid IMT
value
– OR = 3.6 for high IMT
value
Zureik et al. Arterioscl Thromb Vasc Biol 2000;20:1622-9
Carotid atherosclerotic plaque
• Strong predictor of risk
MI Stroke
Salonen JT et al . Arterioscler Thromb 1991;11:1245-9.
Marjolein de Weerd et al. Stroke. 2010;41:1294-1297
Prevalence of Asymptomatic Carotid Artery
Stenosis in the General Population
Severe stenosis in subgroups.
Asymptomatic carotid stenosis
and risk of ipsilateral stroke
Marquardt L et al. Stroke. 2010;41:e11-e17;
Prevention of Stroke/TIA
– Medical Rx
– Revasc
Abbott et al. Stroke 2009;40:e573-e583.
Effet du traitement médical Ipsilateral stroke Any territory stroke
Falls coincide with: (1) Gains in vascular disease understanding (2) Lowering or expansion of thresholds used to define and treat diabetes, hypertension,
hyperlipidemia (3) Progressive use of antiplatelet drugs, blood pressure-lowering drugs, and statins
Courtesy E Touze - Caen
Medical RX
• Antiplatelet therapy
• Blood pressure reduction
• Statin therapy
• Life-style modification
2011 ASA/ACCF/AHA/AANN/
AANS/ACR/ASNR/CNS/SAIP/SCAI/
SIR/SNIS/SVM/SVS Guideline on the
Management of Patients With Extracranial
Carotid and Vertebral Artery Disease
Developed in Collaboration with the American Academy of Neurology and Society of Cardiovascular Computed Tomography
Antiplatelet therapy with aspirin, 75 to 325 mg
daily, is recommended for patients with
obstructive or nonobstructive atherosclerosis
that involves the extracranial carotid and/or
vertebral arteries for prevention of MI and other
ischemic cardiovascular events, although the
benefit has not been established for
prevention of stroke in asymptomatic
patients.
Recommendations for Antithrombotic
Therapy
I IIa IIb III
In patients with obstructive or nonobstructive extracranial carotid or vertebral atherosclerosis who have sustained ischemic stroke or TIA, antiplatelet therapy with aspirin alone (75 to 325 mg daily), clopidogrel alone (75 mg daily), or the combination of aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively) is recommended and preferred over the combination of aspirin with clopidogrel. Selection of an antiplatelet regimen should be individualized on the basis of patient risk factor profiles, cost, tolerance, and other clinical characteristics, as well as guidance from regulatory agencies.
Recommendations for Antithrombotic
Therapy (continued)
I IIa IIb III
Antiplatelet agents are recommended rather than
oral anticoagulation for patients with
atherosclerosis of the extracranial carotid or
vertebral arteries with ischemic symptoms…
or without ischemic symptoms.
Recommendations for Antithrombotic
Therapy (continued)
I IIa IIb III
I IIa IIb III
Stroke Related Mortality and SBP
Lewington S et al. Lancet. 2002 Dec 14;360(9349):1903-13
Antihypertensive drugs and stroke reduction
Law MR. BMJ 2009;338:b1665
Statins and Carotid IMT
Adapté de Amarenco P et al. Stroke. 2004;35:2902-2909.
Meteor CCA
Statins and stroke prevention
• Relationship between ORs for stroke events and corresponding LDL-C reduction
Amarenco P et al, Lancet, 2009;8:453-63.
Statins and stroke prevention
• Meta analysis: 121000 pts
– Stroke RR : 0.84 (95% CI 0.79-0.91).
O’Regan C et al. The American Journal of Medicine (2008) 121, 24-33
Treatment with a statin medication is
recommended for all patients with extracranial
carotid or vertebral atherosclerosis to reduce low-
density lipoprotein (LDL) cholesterol below 100
mg/dL.
Treatment with a statin medication is reasonable
for all patients with extracranial carotid or
vertebral atherosclerosis who sustain ischemic
stroke to reduce LDL-cholesterol to a level near
or below 70 mg/dL.
Control of Hyperlipidemia
I IIa IIb III
I IIa IIb III
Statins and carotid
revascularisation
Study Follow-up Statin Placebo Relative Risk reduction
Heart Protection Study (simvastatine 40 mg/d)
4.6 yrs
All patients 0.4% 0.8% 50%
Prior history of stroke 1.0% 2.3% 56%
SPARCL (atorvastatine 80 mg/d)
5 yrs
Known carotid stenosis 3.2% 7.2% 56%
HPS. Lancet 2004;363:757-67 – Sillesen H et al. Stroke 2008;39:3297-3302.
Algorithm for the management of extracranial
carotid artery disease
ESC Guidelines 2012
Symptomatic stenosis Endarterectomy vs. Medical treatment
Ipsilateral ischemic stroke and any operative stroke or death
Rothwell PM for the CETC. Lancet 2003;361:107-16.
70-99% 50-69%
Operative risks: mortality=1.1% - stroke or death=7.1%
Algorithm for the management of extracranial
carotid artery disease
Asymptomatic Carotid stenosis
Beyond the degree of stenosis
• Clinical features
• Hypoechoic, heterogenous plaque
• Surface irregularity
• Progression of the degree of stenosis
Longstreth WT et al Stroke 1998;29:2371-6
Liapis CD et al. Stroke. 2001;32:2782-2786.
Conclusion
• Les lésions athéroscléreuses des
carotides sont un marqueur du risque
cardiovasculaire global et en particulier de
celui d’AVC
• La prise en charge est médicale avant tout
et devient chirurgicale en cas de lésion
symptomatique